A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

For many struggling with weight management, new medications like Wegovy, Mounjaro, and Saxenda have been seen as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The company behind popular weight-loss drugs failed to disclose even more ... Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...